Hudson Bay Capital Management’s AYTU BioPharma AYTU Stock Holding History

Hudson Bay Capital Management’s Portfolio AYTU Stock Details AYTU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-223	Closed	-$35K	–	696
2018 Q4	$35K	Buy	+223	New	+$49.1K	﹤0.01%	753

Other funds holding AYTU

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Searle & Co Greenwich, Connecticut $445M AUM 41.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Hudson Bay Capital Management's AYTU Position: Q1 2019 in Review

Hudson Bay Capital Management sold out of AYTU BioPharma (AYTU) in Q1 2019, closing a stake of 223 shares — an estimated $35K sold.

Hudson Bay Capital Management first reported a position in AYTU in Q4 2018 and held it in 1 quarter. The position peaked at $35K in Q4 2018. 9 funds tracked by Wall St. Rank hold AYTU as of Q1 2019.

Hudson Bay Capital Management reported no remaining AYTU BioPharma position as of Q1 2019 after selling out during the quarter.
Hudson Bay Capital Management sold 223 AYTU BioPharma shares in Q1 2019, an estimated $35K.
Hudson Bay Capital Management first reported a position in AYTU BioPharma in Q4 2018 and held it in 1 quarter.
Hudson Bay Capital Management's AYTU BioPharma position peaked at $35K in Q4 2018.
9 funds tracked by Wall St. Rank held AYTU BioPharma as of Q1 2019.

Based on Hudson Bay Capital Management's 13F filing for Q1 2019, filed 15 May 2019.